The Lancet Haematology/X
Jun 13, 2025, 23:21
Paul J Bröckelmann Shares The Lancet Haematology Commission Update on Adverse Events at EHA 2025
The Lancet Haematology shared a post on X:
“Today at EHA2025 Dr Paul J Bröckelmann shared insights from The Lancet Haematology Commission on Adverse Events.
Our 2025 Series updates priority areas on measuring and managing toxicities in new haematology treatment.”
Paul J Bröckelmann presented updates from The Lancet Haematology Commission’s 2025 Series at EHA 2025, focusing on improving how adverse events are measured and managed in modern haematology therapies.
You Can Find More Posts on Hemostasis Today.
-
Apr 16, 2026, 06:58Rob Maloney: From Past to Progress in Hemophilia Care in the Dominican Republic
-
Apr 16, 2026, 06:51Michael Ertl: Patient-Reported Outcomes Reveal Differences in Perceived Stroke Recovery
-
Apr 16, 2026, 06:40Susan Shea: Real-Time Platelet Function Assessment in Trauma Patients
-
Apr 16, 2026, 06:36Alan Nurden: Structural Complexity of Contact Sites within Platelet Aggregates
-
Apr 16, 2026, 06:29Aaron Rodriguez Calienes: Grateful to Receive 2nd Consecutive DeSousa Award in Stroke and Interventional Research
-
Apr 16, 2026, 06:24Paul Bolaji: A Growing Movement to Transform Stroke Care in Africa
-
Apr 16, 2026, 05:22Cedric Hermans: A Simple Way to Stay Updated in Haemophilia and von Willebrand Disease
-
Apr 16, 2026, 04:29Vijay Shah: Increasing Value of AI-Based Assessment in Cardiovascular Risk Prediction
-
Apr 16, 2026, 04:13Mysa Saad: Antiplatelets Increase Bleeding Without Reducing VTE in Cancer Patients